LabCorp Extends Offer for Orchid Cellmark

So far, around 82 percent of Orchid's outstanding stock has been tendered in the offer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories